Identification of a novel agonist of peroxisome proliferator-activated receptors α and γ that may contribute to the anti-diabetic activity of guggulipid in Lepob/Lepob mice

Journal of Nutritional Biochemistry

Volumn 20, Issue 10, 2009, Pages 806-815

  Cornick, Claire L ^a   Strongitharm, Barbara H ^b   Sassano, Gary ^b   Rawlins, Christopher ^b   Mayes, Andrew E ^b   Joseph, Alison N ^b   O'Dowd, Jacqueline ^a   Stocker, Claire ^a   Wargent, Ed ^a   Cawthorne, Michael A ^a   Brown, A Louise ^b   Arch, Jonathan R S ^a  

^a UNIVERSITY OF BUCKINGHAM   (United Kingdom)

^b UNILEVER RESEARCH   (United Kingdom)

Author keywords

Commipheric acid; Diabetes; Guggulipid; Lepob Lepob mouse; Liver X receptor ; Peroxisome proliferator activated receptor

Indexed keywords

CIGLITAZONE; COMMIPHERIC ACID; GLUCOSE; GUGGULSTERONE; GUKKASELECT; INSULIN; LIVER X RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL DIFFERENTIATION; CELL STRAIN COS7; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DRUG POTENCY; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; LIVER WEIGHT; MOUSE; NONHUMAN; PROADIPOCYTE; TRIACYLGLYCEROL BLOOD LEVEL;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; CERCOPITHECUS AETHIOPS; COMMIPHORA; COS CELLS; DNA PRIMERS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LEPTIN; MICE; MICE, INBRED C57BL; OBESITY; PLANT EXTRACTS; PLANT GUMS; PPAR ALPHA; PPAR GAMMA;

COMMIPHORA WIGHTII; MUS;

EID: 69749112698     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2008.07.010     Document Type: Article

References (43)

1. Egan C.D. Addressing use of herbal medicine in the primary care setting. J Am Acad Nurse Pract 14 (2002) 166-171
2. Raskin I., Ribnicky D.M., Komarnytsky S., Ilic N., Poulev A., Borisjuk N., et al. Plants and human health in the twenty-first century. Trends Biotechnol 20 (2002) 522-531
3. Satyavati G.V. Gum guggul (Commiphora mukul) - the success story of an ancient insight leading to a modern discovery. Indian J Med Res 87 (1988) 327-335
4. Szapary P.O., Wolfe M.L., Bloedon L.T., Cucchiara A.J., DerMarderosian A.H., Cirigliano M.D., et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 290 (2003) 765-772
5. Urizar N.L., and Moore D.D. Gugulipid: a natural cholesterol-lowering agent. Annu Rev Nutr 23 (2003) 303-313
6. Ulbricht C., Basch E., Szapary P., Hammerness P., Axentsev S., Boon H., et al. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med 13 (2005) 279-290
7. Deng R. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc Drug Rev 25 (2007) 375-390
8. Urizar N.L., Liverman A.B., Dodds D.T., Silva F.V., Ordentlich P., Yan Y., et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296 (2002) 1703-1706
9. Cui J., Huang L., Zhao A., Lew J.L., Yu J., Sahoo S., et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem 278 (2003) 10214-10220
10. Brobst D.E., Ding X., Creech K.L., Goodwin B., Kelley B., and Staudinger J.L. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J Pharmacol Exp Ther 310 (2004) 528-535
11. Owsley E., and Chiang J.Y. Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene. Biochem Biophys Res Commun 304 (2003) 191-195
12. Ding X., and Staudinger J.L. The ratio of constitutive androstane receptor to pregnane X receptor determines the activity of guggulsterone against the Cyp2b10 promoter. J Pharmacol Exp Ther 314 (2005) 120-127
13. Burris T.P., Montrose C., Houck K.A., Osborne H.E., Bocchinfuso W.P., Yaden B.C., et al. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol Pharmacol 67 (2005) 948-954
14. Subramaniam A., Stocker C., Sennitt M.V., Wang S., Nolan A.L., Brown L., et al. Guggul lipid reduces insulin resistance and body weight gain in C57Bl/6 lep/lep mice. Int J Obes 25 Suppl 2 (2001) S24
15. Bosley J.M., Brown A.L., and Roger J.S. Food compositions for reducing insulin resistance. United States Patent 6737442 (2004)
16. Kimura I., Yoshikawa M., Kobayashi S., Sugihara Y., Suzuki M., Oominami H., et al. New triterpenes, myrrhanol A and myrrhanone A, from guggul-gum resins, and their potent anti-inflammatory effect on adjuvant-induced air-pouch granuloma of mice. Bioorg Med Chem Lett 11 (2001) 985-989
17. Matsuda H., Morikawa T., Ando S., Oominami H., Murakami T., Kimura I., et al. Absolute stereostructures of polypodane-type triterpenes, myrrhanol A and myrrhanone A, from guggul-gum resin (the resin of Balsamodendron mukul). Chem Pharm Bull (Tokyo) 52 (2004) 1200-1203
18. Sher T., Yi H.F., McBride O.W., and Gonzalez F.J. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32 (1993) 5598-5604
19. Joseph S.B., Laffitte B.A., Patel P.H., Watson M.A., Matsukuma K.E., Walczak R., et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 277 (2002) 11019-11025
20. Laffitte B.A., Joseph S.B., Walczak R., Pei L., Wilpitz D.C., Collins J.L., et al. Autoregulation of the human liver X receptor alpha promoter. Mol Cell Biol 21 (2001) 7558-7568
21. Mak P.A., Laffitte B.A., Desrumaux C., Joseph S.B., Curtiss L.K., Mangelsdorf D.J., et al. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J Biol Chem 277 (2002) 31900-31908
22. Kasturi R., and Joshi V.C. Hormonal regulation of stearoyl coenzyme A desaturase activity and lipogenesis during adipose conversion of 3T3-L1 cells. J Biol Chem 257 (1982) 12224-12230
23. Fleming W.W., Westfall D.P., De la Lande I.S., and Jellett L.B. Log-normal distribution of equieffective doses of norepinephrine and acetylcholine in several tissues. J Pharmacol Exp Ther 181 (1972) 339-345
24. Mukherjee R., Hoener P.A., Jow L., Bilakovics J., Klausing K., Mais D.E., et al. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 14 (2000) 1425-1433
25. Hurst C.H., and Waxman D.J. Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol Sci 74 (2003) 297-308
26. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 171 (2003) 1-13
27. Haluzik M.M., and Haluzik M. PPAR-alpha and insulin sensitivity. Physiol Res 55 (2006) 115-122
28. Owens D.R. Thiazolidinediones - A pharmacological overview. Clin Drug Investig 22 (2002) 485-505
29. Carmona M.C., Louche K., Nibbelink M., Prunet B., Bross A., Desbazeille M., et al. Fenofibrate prevents rosiglitazone-induced body weight gain in ob/ob mice. Int J Obes Relat Metab Disord 29 (2005) 864-871
30. Allen T., Zhang F., Moodie S.A., Clemens L.E., Smith A., Gregoire F., et al. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes 55 (2006) 2523-2533
31. Rocchi S., Picard F., Vamecq J., Gelman L., Potier N., Zeyer D., et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8 (2001) 737-747
32. Misra P., Chakrabarti R., Vikramadithyan R.K., Bolusu G., Juluri S., Hiriyan J., et al. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. J Pharmacol Exp Ther 306 (2003) 763-771
33. Hu X., Feng Y., Shen Y., Zhao X.F., Yu J.H., Yang Y.S., et al. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice. Acta Pharmacol Sin 27 (2006) 1346-1352
34. Chakrabarti R., Vikramadithyan R.K., Misra P., Hiriyan J., Raichur S., Damarla R.K., et al. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol 140 (2003) 527-537
35. Han K.L., Choi J.S., Lee J.Y., Song J., Joe M.K., Jung M.H., et al. Therapeutic potential of peroxisome proliferators-activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes 57 (2008) 737-745
36. Hummasti S., Laffitte B.A., Watson M.A., Galardi C., Chao L.C., Ramamurthy L., et al. Liver X receptors are regulators of adipocyte gene expression but not differentiation: identification of apoD as a direct target. J Lipid Res 45 (2004) 616-625
37. Seo J.B., Moon H.M., Kim W.S., Lee Y.S., Jeong H.W., Yoo E.J., et al. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol 24 (2004) 3430-3444
38. Juvet L.K., Andresen S.M., Schuster G.U., Dalen K.T., Tobin K.A., Hollung K., et al. On the role of liver x receptors in lipid accumulation in adipocytes. Mol Endocrinol 17 (2003) 172-182
39. Krook A. Can the liver X receptor work its magic in skeletal muscle too?. Diabetologia 49 (2006) 819-821
40. Laffitte B.A., Chao L.C., Li J., Walczak R., Hummasti S., Joseph S.B., et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A 100 (2003) 5419-5424
41. Cao G., Liang Y., Broderick C.L., Oldham B.A., Beyer T.P., Schmidt R.J., et al. Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 278 (2003) 1131-1136
42. Grefhorst A., van Dijk T.H., Hammer A., van der Sluijs F.H., Havinga R., Havekes L.M., et al. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab 289 (2005) E829-E838
43. Liu Y., Yan C., Wang Y., Nakagawa Y., Nerio N., Anghel A., et al. Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology 147 (2006) 5061-5068